BioXcel Therapeutics Operating Margin vs. Cash Per Share

BTAI Stock  USD 0.43  0.01  2.27%   
Based on BioXcel Therapeutics' profitability indicators, BioXcel Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess BioXcel Therapeutics' ability to earn profits and add value for shareholders. The current Price To Sales Ratio is estimated to decrease to 59.16. The current Days Sales Outstanding is estimated to decrease to 17.84. As of now, BioXcel Therapeutics' Interest Income is increasing as compared to previous years. The BioXcel Therapeutics' current Non Operating Income Net Other is estimated to increase to about 2.5 M, while Operating Income is forecasted to increase to (163.2 M).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.08260.087
Notably Down
Slightly volatile
For BioXcel Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of BioXcel Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well BioXcel Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between BioXcel Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of BioXcel Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioXcel Therapeutics. If investors know BioXcel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioXcel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.04)
Revenue Per Share
0.074
Quarterly Revenue Growth
1.416
Return On Assets
(0.64)
Return On Equity
(17.67)
The market value of BioXcel Therapeutics is measured differently than its book value, which is the value of BioXcel that is recorded on the company's balance sheet. Investors also form their own opinion of BioXcel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is BioXcel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioXcel Therapeutics' market value can be influenced by many factors that don't directly affect BioXcel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioXcel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioXcel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioXcel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

BioXcel Therapeutics Cash Per Share vs. Operating Margin Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining BioXcel Therapeutics's current stock value. Our valuation model uses many indicators to compare BioXcel Therapeutics value to that of its competitors to determine the firm's financial worth.
BioXcel Therapeutics is rated below average in operating margin category among its peers. It is rated third in cash per share category among its peers . As of now, BioXcel Therapeutics' Operating Profit Margin is increasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the BioXcel Therapeutics' earnings, one of the primary drivers of an investment's value.

BioXcel Cash Per Share vs. Operating Margin

Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

BioXcel Therapeutics

Operating Margin

 = 

Operating Income

Revenue

X

100

 = 
(14.89) %
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.

BioXcel Therapeutics

Cash Per Share

 = 

Total Cash

Average Shares

 = 
8.33 X
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.

BioXcel Cash Per Share Comparison

BioXcel Therapeutics is currently under evaluation in cash per share category among its peers.

BioXcel Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in BioXcel Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, BioXcel Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of BioXcel Therapeutics' change in net profit over the period of time. It can combine multiple indicators of BioXcel Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Operating Income-171.8 M-163.2 M
Income Before Tax-179.1 M-170.1 M
Net Loss-149.2 M-141.7 M
Net Loss-179.1 M-170.1 M
Net Interest Income-6.6 M-6.3 M
Net Loss-211.6 M-201 M
Total Other Income Expense Net-7.3 M-6.9 M
Income Tax Expense150.1 K142.6 K
Interest Income6.2 M6.5 M
Non Operating Income Net Other2.4 M2.5 M
Change To Netincome21.3 M22.4 M
Net Loss(6.15)(5.84)
Income Quality 0.87  0.56 
Net Income Per E B T 0.93  0.80 

BioXcel Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on BioXcel Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of BioXcel Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the BioXcel Therapeutics' important profitability drivers and their relationship over time.

Use BioXcel Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioXcel Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioXcel Therapeutics will appreciate offsetting losses from the drop in the long position's value.

BioXcel Therapeutics Pair Trading

BioXcel Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to BioXcel Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioXcel Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioXcel Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BioXcel Therapeutics to buy it.
The correlation of BioXcel Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioXcel Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioXcel Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BioXcel Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your BioXcel Therapeutics position

In addition to having BioXcel Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run ESG Investing Thematic Idea Now

ESG Investing
ESG Investing Theme
Sustainable investments that promote the conservation of the natural world, social resposibility, freindly employees policies and strong governance. The ESG Investing theme has 51 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize ESG Investing Theme or any other thematic opportunities.
View All  Next Launch
When determining whether BioXcel Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioXcel Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bioxcel Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bioxcel Therapeutics Stock:
Check out Trending Equities.
For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.
You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
To fully project BioXcel Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of BioXcel Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include BioXcel Therapeutics' income statement, its balance sheet, and the statement of cash flows.
Potential BioXcel Therapeutics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although BioXcel Therapeutics investors may work on each financial statement separately, they are all related. The changes in BioXcel Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on BioXcel Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.